Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The study is designed to determine the use of delivering point of care, rapid diagnosis with
rK39 and treatment with AmBisome single dose of 10 mg/kg when administrated in the Primary
Health Center (PHC) settings with regard to operational feasibility, safety and final cure
rate at 6 months after end of treatment. Point of care diagnosis and treatment (PCDT) at the
PHC level would bring the best available interventions closer to the patients with visceral
leishmaniasis (VL) whose villages are within several kilometers of the PHC. This would
support the VL elimination program in the Indian subcontinent.
Phase:
Phase 4
Details
Lead Sponsor:
Banaras Hindu University
Collaborator:
Rajendra Memorial Research Institute of Medical Sciences